Arcellx presents CART-ddBCMA Phase 1 expansion data at ASH; no specific results disclosed in 8-K

Arcellx, Inc.

Event at 65th ASH Annual Meeting on Dec 11, 2023 in San Diego highlighting CART-ddBCMA Phase 1 expansion trial.
Trial enrolled patients with relapsed/refractory multiple myeloma.
Filing does not include numerical efficacy or safety data from the presentation.
Corporate slides attached as Exhibit 99.1 but full data not reproduced in this filing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.